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Abstract 
Staurosporine in the micromolar range raised inositol trisphosphate in intact human platelets to levels comparable to that mediated by thrombin. 
This response was inhibited by neomycin, a phospholipase C antagonist. Staurosporine alone induced a weak, transient rise in cytosolic free calcium 
levels ([Ca2’]J from release of internal Ca*+ stores but potentiated the effect induced by thrombin. Therefore, it is unlikely that this alkaloid suppressed 
inositol trisphosphate mobilization of Ca2’. Additional studies show that staurosporine, OS-5 ,uM, stimulated GTPase activity in platelet membranes 
while 2 PM K252a and 20 FM H7 were inactive. Present results suggest hat staurosporine may activate platelet phospholipase C at the level of G 
proteins or receptors. 
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1. lntrodwtion 
Staurosporine, a microbial alkaloid from Streptomy- 
ces sp. is a potent but nonspecific inhibitor of protein 
kinase C (PI(C) (IC,, of 3 nM) [l]. This reagent has been 
used in numerous studies to inhibit PKC-dependent re- 
sponses in platelets [3-61. Recently we showed that stau- 
rosporine in the micromolar range causes a rapid and 
sustained elevation of cytosolic free Ca” concentration 
([Ca”+]J in neutrophils via an indirect mechanism [7f. 
Subsequently, Himpens and coworkers [S] reported that 
staurosporine mobilizes intra~ll~ar Ca” stores and in- 
duces Ca2’ influx in cultured DDTlMF-2 smooth mus- 
cle cells. In both studies, the effect of staurosporine on 
[Ca2’]i is not correlated with PKC inhibition or phos- 
pholipase C (PLC) activation. The present study was 
undertaken to investigateand compare the effect of stau- 
rosporine on [Ca2’]i in human platelets. We report here 
that micromolar staurosporine induced significant hy- 
drolysis of phosphatidyl inositol4,5-bisphosphate (PIP2) 
but weak transient elevations of [Ca2’J,. 
*Corresponding author. Fax: (1) (403) 541 4466. 
Abbreviations: PIPZ, phosphatidylinositol 4,5-bisphosphate; InsP,, 
inositol trisphosphate; Ins(1,4,5)P,, inositol 1,4,5&sphosphate; PKC, 
protein kinase C; PLC, phospholipase C; G protein, heterotrimeric 
guanine nucleotide-binding regulatory protein, [Ca2+Ji, cytosolic free 
Ca2’ concentration; TX, thromboxane; Me,SO, dimethyl sulfoxide. 
2. Materials and methods 
2.1. Materials 
[‘H]Myo-inositol, (W-120 Ciimmol) and a ligand binding assay kit 
for Ins(1,4,5)P, were from Amersham Canada Ltd. (Oakville, Qnt.); 
human thrombin, apyrase, neomycin sulfate, and prostacyclin were 
from Sigma Chemical Co. (St. Louis, MO); staurosporine was obtained 
from Sigma and Boehringer Mannheim (Montreal, P.Q.); Fura- AM 
and ionomycin were from Calbiochem Corp. (San Diego, CA); Stock 
solutions of staurosporine and ionomycin were dissolved in dimethyl 
sulfoxide (MesSO) and stored at -80°C. 
2.2. separation of platelet ~pe~~n 
Blood was drawn by ve~p~cture from drug-free volunteers into 116 
volume acid citrate dextrose. Platelet-rich plasma was obtained by 
centrifuging whole blood at 300 x g at room temperature for 15 min. 
After careful removal, the plasma was further centrifuged at 2500 x g 
at room temperature for 10 min to pellet the platelets. Platelets were 
resuspended in Tyrode-HEPES buffer (134 mM NaCl, 12 mM 
NaHCO,, 2.9 mM KCl, 0.36 mM NaH,PQ4, 1 mM MgCl,, 5 mM 
HEPES,J mM glucose; pH 7.2) containing apyrase (0.6 ADPase U/ml) 
and 0.35% bovine serum albumin. For labeling platelets with [3H]myo- 
inositol, the buffer also contained 1 mM EGTA and 500 ng/ml prosta- 
cyclin [9]. 
2.3. Assay for Inositoi phosphates 
Inositol phosphate formation in platelets was assayed according to 
procedures described by Lapetina and Siess [9]. Briefly, platelets prela- 
beled with [3~y~inositol at a density of 8 x 10’ cells/ml Tyrode- 
HEPES were incnbated with agonists then stopped with chloroforml 
methanol&ICI. The neutralized aqueous phases were applied to Dowex 
l-X8 anion-exchange columns (formate form) and radio-labelled inosi- 
to1 mono-, bis-, and trisphosphates (InsP,) were eluted by washing 
columns with ammonium formate/formic acid. 
Inositol 1,4,5-t&phosphate (Ins(1,4,5)P,) was quantitated by a com- 
petitive ligand-binding assay previously applied to neutrophil studies 
in this laboratory [7,10]. Platelet suspensions (5-6 x 10g/ml) were 
treated with trichloroacetic acid and Ins(1,4,5)P3 levels in supernatant 
extracts were quantitated according to the protocol supplied by Amer- 
sham. The major cross reactivities were 0.22% and 6.4% for n-myo- 
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inositol 1,3,4-trisphosphate and n-myo-inositol 1,3,4,.5-tetrakis- 
phosphate respectively. 
2.4. Measurement of [Cd’]; 
Platelets (8 x lO*/ml) were loaded with fura- by incubation at 37°C 
with 1 PM Fura- AM for 45 min [ll]. Washed platelets (2.0 ml at 
3 x lO*/ml) were measured for changes in fluorescence at monochroma- 
tor settings of 339 nm (excitation) and 505 mn (emission). [Ca’+J was 
calculated as described previously 17,101. 
2.5. GTPase assay for platelet membranes 
Lysates of human platelets were obtained by rapid freezing and 
thawing in 10 mM triet~nol~ine-HCI, pH 7.4, containing 5 mM 
EDTA. Lysed platelets were ~n~uged for 20 min at 30,O~ x R at 
4°C. The-pellet was washed twice in the same medium and finally 
suspended in 10 mM triethanolamine-HCl, pH 7.4, without EDTA. 
GTPase activity was measured according to previously published pro- 
cedures 112,131. Reactions were carried out in 100 fil, 50 mM trieth- 
anolamine-HCl, pH 7.4, containing the following: 0.1-0.3 PM 
Ir-“PlGTP. (0.1 uCi/tube): 0.1 mM ATP: 0.1 mM EGTA: 2 mM 
&lgCi,; 1 m&i dithiothrei;bl, 5 mM creature phosphate; 0.4 mglml 
creatine kinase; 2 mg/ml bovine serum albumin, Reactions were started 
by adding platelet membranes (5-10 pg protein/tube) and stopped by 
the addition of 0.5 ml ice-cold sodium ohosnhate buffer (20 mM). DH 
7.0, containing 5% (w/v) activated chaicoal: High-affinity GTPase ac- 
tivity was calculated from the diierence between total “Pi released in 
the presence of 0.3 yM GTP and that formed in the presence of 50 PM 
GTP. All reactions were done in triplicate. 
3. Results 
In studies with platelets suspended in Ca2+-free me- 
dium, staurosporine, up to 4 PM, induced weak transient 
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rises in [Ca*+]i (Fig. lA, traces a,b) which was not ob- 
tained with Me&30 alone (trace c). Subsequent addition 
of Ca2’ failed to affect [Ca2+]i. The apparent increase in 
the signal was due to Ca*’ complexing with small 
amounts of extracellular fura- since Tris-EGTA de- 
pressed it quickly (traces b,c). In the same traces, throm- 
bin elevated [Ca”‘]i in platelets from about 0.1 PM 
to > 0.5 PM (trace a). In most cases, the rise in [Ca2’li 
peaked at less than 10-15 s and declined gradually to 
basal levels over several min. When platelets were sus- 
pended in medium with 1 mM Ca*‘, staurospo~ne pro- 
duced an equally transient increase in [Ca*+]i (trace d). 
Here, pretreatment with staurosporine potentiated the 
effect of thrombin on platelet [C!a2”]i. The extent and 
duration of the rise in [Ca*‘]i was increased compared 
with the response induced in cells treated with thrombin 
alone (trace e). 
Mn2+ entry into platelets and consequent quenching of 
fura- fluorescence was employed as an indirect meas- 
urement of Ca2+ influx (Fig. 1B) [7,10]. Mn2* added to 
resting platelets produced a basal rate of quenching due 
to entry via leak channels. ~rombin activation of cells 
accelerated Mn2+ entry in agreement with previous re- 
ports [14]. Staurosporine, 2 PM, on the other hand, nei- 
ther affected the basal rate nor interfered with Mn” 
entry mediated by ionomycin. The results in Fig. 1A and 
B indicate that staurosporine induced a limited release 
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Fig. 1, (A) The effect of staurosporine on [Ca2Ti of human platelets. Human platelets preloaded with fura- and resuspended inTyrode-HEPES buffer 
were treated with staurosporine (STA) and reagents in the order shown in the figure. Final concentrations were 1 U/ml thrombin (THR), 1 mM CaCl*, 
25 mM T&-base and 2 mM ethylene glycol bis(B-aminoethyl ether) NJ’-tetraacetic acid (EGTA). Fluorescence measurements and calculation of 
[Ca2’li (except for traces b and c) were carried out as outlined in section 2. In traces (d) and (e), the medium was supplemented with 1 mM CaCl,. 
Results are representative of four experiments. (B) Kinetics of Mn2’ quenching of fluorescence in thrombin- and staurosporine-treated platelets. 
Fura- loaded platelets were stimulated with reagents in the following order: trace (a) Mn2+ , staurosporine, ionomycin; trace (b), Mn”; trace (c) 
Mn”, thrombin. The excitation wavel~gth used was 360 ran (isobestic wavelength for Ca2’). Results are representative of three experiments. 
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Fig. 2. Time course of [3H]InsP, formation in human platelets treated 
with thrombin or staurosporine. Human platelets prelabeled with 
[‘Hlmyo-inositol were incubated with thrombin, 2 U/ml (n), stauro- 
sporine, 1.0 PM (o), 2.0 PM (0) or Me,SO (0), for up to 120 s. 
Reactions were stopped and inositol phosphate levels determined as 
described in section 2. Results were calculated as % of basal radioac- 
tivity in Me,SO-treated cells at 0 time. Each point represents the 
mean k S.E.M. of four separate xperiments. 
of intracellular Ca*+ without an accompanying influx of 
cations. 
PLC activity in platelets prelabeled with [31-Ilmyo- 
inositol was measured as rises in [3H]-(InsP3). (InsP, iso- 
mers were not resolved by anion-exchange chromatogra- 
phy.) Positive controls show that thrombin induced 
rapid hydrolysis of PIP2; InsP, levels were maximally 
elevated at the earliest ime sampled (10 s) after thrombin 
addition to platelets. Thereafter, InsP, activity declined 
towards basal levels (Fig. 2). Staurosporine, l-2 ,uM, 
also induced rapid formation of InsP, which plateaued 
at 15-20 s but remained elevated after 2 min. The maxi- 
mal levels of InsP, detected were similar to that found for 
thrombin. This response was dose-dependent with signif- 
icant InsP, formation occurring at submicromolar con- 
centrations of staurosporine (Fig. 3). Staurosporine-de- 
pendent InsP3 formation was abolished when platelets 
were treated with 20 mM neomycin, an inhibitor of 
phosphoinositide signalling [15]. This result among oth- 
ers suggests that staurosporine increased InsP, levels by 
activation of the PLC-PIP2 hydrolysis pathway. 
The product of the preceding pathway, Ins(1,4,5)P,, 
was specifically quantitated using a competitive binding 
assay for this second messenger. Results show that 2 ,uM 
staurosporine elevated Ins(1,4,5)P, to about 50% of lev- 
els induced by thrombin (Fig. 4). The lower amount of 
Ins(1,4,5)P, detected by this method compared with re- 
sults obtained by anion-exchange chromatography may 
arise from the presence of species other than Ins( 1 ,4,5)P3 
in the InsP, fraction eluted from columns. Besides InsP, 
isomers, this fraction contains contaminating [3H]inosi- 
to1 mono- and bisphosphates [9]. 
Further studies show that staurosporine increased the 
linear rate of GTP hydrolysis in crude platelet mem- 
branes. As the results in Fig. 5 indicate, staurosporine 
increased the GTPase activity in a dose-dependent man- 
ner; 5 ,uM staurosporine was as potent as thrombin in 
stimulating GTPase. By comparison, the kinase inhib- 
itors, K252a (2 PM) (structurally related to stauro- 
sporine [l]), and H7 (20 PM) did not significantly affect 
this activity at the concentrations tested. 
4. Discussion 
Based on results of assays for inositol phosphates, we 
conclude that micromolar concentrations of stauro- 
sporine activated the PIPUPLC pathway in human 
platelets. The suppression of InsP, formation by neo- 
mycin, a known inhibitor of phosphoinositide signalling, 
further implicates the involvement of PLC (Fig. 3). Un- 
like thrombin which caused a transient rise in InsP,, 
staurosporine produced a sustained elevation if InsP, 
(Fig. 2). This may be due partly to concurrent inhibition 
of PKC-dependent reactions which convert Ins( 1 ,4,5)P3 
to other inositol phosphates. Previously, King and Rit- 
tenhouse [3] found that PKC promotes the metabolism 
of Ins( 1 ,4,5)P3 to other inositol phosphates by enhancing 
the activities of InsP, 5-phosphatase and 3-kinase. 
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Fig. 3. Dose-response ffect of staurosporine on platelet InsP, and the 
effect of neomycin. [‘H]InsP,recovered from platelets after 60 s incu- 
bation with staurosporine (GO) or staurosporine plus 20 mM neo- 
mycin (u) were calculated as % of basal radioactivity in Me,SO- 
treated cells. Results represent he mean + S.E.M. of 4 (0) or 3 (e) 
separate xperiments. 
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platelet responses uch as aggregation and degranulation 
[2-51. We note that Murphy et al. [4] reported no effect 
for 1 PM staurosporine on Ins(1,4,5)P, in rabbit plate- 
lets. Species differences may account for the difference 
in results. Besides its stimulation of PLC described here, 
staurosporine has been shown to both inhibit and acti- 
vate subsets of serine/threonine kinases in platelets [181. 
A puzzling finding of present experiments was that 
staurosporine induced a weak response on platelet 
[Ca2+]i compared with its effect on InsP,. Staurosporine 
inhibition of Ca” mobilization by Ins(1,4,5)P3 is un- 
likely since it potentiated rather than inhibited the effect 
of thrombin on platelet [Ca2+]i (Fig. 1). Other factors 
may account for its weak effect on [Ca”]i. Firstly, aver- 
age changes in cellular InsP, are not necessarily corre- 
lated with increases in [Ca2+]i [19]. Secondly, initial in- 
creases in [Ca2+]i triggered by platelet agonists are am- 
plified by phospholipase A2 activation and TXA, for- 
mation [20-221. It is possible that staurosporine failed to 
activate the amplification pathway or that it blocks am- 
plification at an early step. Direct staurosporine inhibi- 
tion of TXA, synthesis can be ruled out since 1 PM 
staurosporine has been shown to enhance thromboxane 
formation in platelets stimulated by platelet activating 
factor [4]. 
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Fig. 4. Ins(1,4,5)P, formation in staurosporine- or thrombin-treated 
platelets. Ins(1,4,5)P, levels in platelets incubated for 15 s with throm- 
bin, staurosporine or Me,SO were quantified by the Ins( 1,4,5)P3 ligand 
binding assay as described in section 2. Values are the mean + S.E.M. 
of three separate xperiments. *Significantly different compared with 
Me,SO control values (P < 0.05) by the Student’s paired t-test. 
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Endowment Fund. The mechanism by which staurosporine activated PLC 
in platelets remains to be elucidated. Indirect activation 
via thromboxane A, (TXA,) generation appears unlikely 
as assays for its metabolite, TXB2, by a radioimmunoas- 
say method (NEN, DuPont) failed to detect significant 
amounts of this agent (results not shown). It is possible 
that staurosporine interacted directly with a receptor or 
a G protein coupled to PLC. The latter conjecture is 
supported by Kanaho and coworkers’ experiments 
showing that staurosporine activates purified Gil recon- 
stituted into phospholipid vesicles [16]. Also in keeping 
with this hypothesis is the finding that staurosporine 
stimulated GTPase activity in platelet membranes (Fig. 
5). 
There is evidence that PIP2 hydrolysis in platelets may 
also be mediated by a tyrosine kinase-activated phospho- 
lipase C-gamma [17]. However it is unlikely that stauro- 
sporine activated this pathway since it inhibits tyrosine 
kinase activities [ 171. 
Additional studies found that micromolar stauro- 
sporine did not induce platelets to aggregate or to secrete 
5-hydroxytryptamine (results not shown). These results 
are not surprising since staurosporine itself inhibited 
PKC and caused only a weak rise in [Ca2+]i - two impor- 
tant components for signal transduction in platelets. 
These negative results agree with findings reported by 
various groups which have used up to 10 PM stauro- 
sporine to inhibit platelet PKC. Heretofore, control as- 
says showed that staurosporine on its own does not elicit 
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Fig. 5. GTPase activity of platelet membranes treated with stauro- 
spoke. Platelet membranes were prepared and incubated at room 
temperature for 10 min in the presence of thrombin, 2 U/ml; vehicle 
control, 0.4% Me,SO; staurosporine, 0.1 to 5 PM; K252a, 2 PM; and 
H7, 20 PM. Results are the average ( + S.E.M.) of 4 experiments. 
*Significantly different from vehicle control at P < 0.05. 
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